These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

441 related articles for article (PubMed ID: 28378904)

  • 41. Methods for identification of Candida auris, the yeast of global public health concern: A review.
    Mahmoudi S; Agha Kuchak Afshari S; Aghaei Gharehbolagh S; Mirhendi H; Makimura K
    J Mycol Med; 2019 Jun; 29(2):174-179. PubMed ID: 31031132
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Candida auris in Germany and Previous Exposure to Foreign Healthcare.
    Hamprecht A; Barber AE; Mellinghoff SC; Thelen P; Walther G; Yu Y; Neurgaonkar P; Dandekar T; Cornely OA; Martin R; Kurzai O;
    Emerg Infect Dis; 2019 Sep; 25(9):1763-1765. PubMed ID: 31223105
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Identification and typing of the emerging pathogen Candida auris by matrix-assisted laser desorption ionisation time of flight mass spectrometry.
    Girard V; Mailler S; Chetry M; Vidal C; Durand G; van Belkum A; Colombo AL; Hagen F; Meis JF; Chowdhary A
    Mycoses; 2016 Aug; 59(8):535-8. PubMed ID: 27292939
    [TBL] [Abstract][Full Text] [Related]  

  • 44.
    Kohlenberg A; Struelens MJ; Monnet DL; Plachouras D;
    Euro Surveill; 2018 Mar; 23(13):. PubMed ID: 29616608
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Candida rugosa: a distinctive emerging cause of candidaemia. A case report and review of the literature.
    Minces LR; Ho KS; Veldkamp PJ; Clancy CJ
    Scand J Infect Dis; 2009; 41(11-12):892-7. PubMed ID: 19922077
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Approach to the Investigation and Management of Patients With Candida auris, an Emerging Multidrug-Resistant Yeast.
    Tsay S; Kallen A; Jackson BR; Chiller TM; Vallabhaneni S
    Clin Infect Dis; 2018 Jan; 66(2):306-311. PubMed ID: 29020224
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Evaluation of antifungal susceptibility testing in Candida isolates by Candifast and disk-diffusion method.
    Giri S; Kindo AJ
    Indian J Pathol Microbiol; 2014; 57(4):595-7. PubMed ID: 25308014
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Neonatal Candida infections and the antifungal susceptibilities of the related Candida species].
    Altuncu E; Bilgen H; Cerikçioğlu N; Ilki A; Ulger N; Bakır M; Akman I; Ozek E
    Mikrobiyol Bul; 2010 Oct; 44(4):593-603. PubMed ID: 21063972
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Esophagitis caused by Candida guilliermondii in diabetes mellitus: first reported case.
    Macêdo DP; Oliveira NT; Farias AM; Silva VK; Wilheim AB; Couto FM; Neves RP
    Med Mycol; 2010 Sep; 48(6):862-5. PubMed ID: 20144130
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Community-acquired fungemia due to a multiple-azole-resistant strain of Candida tropicalis.
    Jandourek A; Brown P; Vazquez JA
    Clin Infect Dis; 1999 Dec; 29(6):1583-4. PubMed ID: 10585825
    [No Abstract]   [Full Text] [Related]  

  • 51. In vitro susceptibility of breakthrough Candida bloodstream isolates correlates with daily and cumulative doses of fluconazole.
    Clancy CJ; Staley B; Nguyen MH
    Antimicrob Agents Chemother; 2006 Oct; 50(10):3496-8. PubMed ID: 17005842
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Insights into the Unique Nature of the East Asian Clade of the Emerging Pathogenic Yeast Candida auris.
    Welsh RM; Sexton DJ; Forsberg K; Vallabhaneni S; Litvintseva A
    J Clin Microbiol; 2019 Apr; 57(4):. PubMed ID: 30760535
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Take control over your fluconazole prescriptions: the growing importance of Candida glabrata as an agent of candidemia in Brazil.
    Pasqualotto AC; Zimerman RA; Alves SH; Aquino VR; Branco D; Wiltgen D; do Amaral A; Cechinel R; Colares SM; da Rocha IG; Severo LC; Sukiennik TC
    Infect Control Hosp Epidemiol; 2008 Sep; 29(9):898-9. PubMed ID: 18785850
    [No Abstract]   [Full Text] [Related]  

  • 54. Candida auris: an Emerging Fungal Pathogen.
    Spivak ES; Hanson KE
    J Clin Microbiol; 2018 Feb; 56(2):. PubMed ID: 29167291
    [No Abstract]   [Full Text] [Related]  

  • 55. [Antifungal susceptibility of Candida species isolated from patient with invasive fungal peritonitis and investigation on clinical breakpoints of itraconazole].
    Yamagishi Y; Terada M; Ohki E; Mikamo H
    Jpn J Antibiot; 2009 Oct; 62(5):415-34. PubMed ID: 20055119
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Biofilm-Forming Capability of Highly Virulent, Multidrug-Resistant Candida auris.
    Sherry L; Ramage G; Kean R; Borman A; Johnson EM; Richardson MD; Rautemaa-Richardson R
    Emerg Infect Dis; 2017 Feb; 23(2):328-331. PubMed ID: 28098553
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The lurking scourge of multidrug resistant Candida auris in times of COVID-19 pandemic.
    Chowdhary A; Sharma A
    J Glob Antimicrob Resist; 2020 Sep; 22():175-176. PubMed ID: 32535077
    [No Abstract]   [Full Text] [Related]  

  • 58. Identification and antifungal susceptibility of Candida isolated from intensive care unit patients.
    Zer Y; Balci I; Meriç G
    New Microbiol; 2002 Oct; 25(4):489-94. PubMed ID: 12437230
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Candida auris in critically ill patients: Emerging threat in intensive care unit of hospitals.
    Das S; Rai G; Tigga RA; Srivastava S; Singh PK; Sharma R; Datt S; Singh NP; Dar SA
    J Mycol Med; 2018 Sep; 28(3):514-518. PubMed ID: 30042047
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Containment strategies to address the expanding threat of multidrug-resistant Candida auris.
    McCarthy MW; Walsh TJ
    Expert Rev Anti Infect Ther; 2017 Dec; 15(12):1095-1099. PubMed ID: 29110544
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.